Miflonide Breezhaler (Budesonide)

Budesonide binds to glucocorticoid receptors in the cells lining the airways, altering gene expression to suppress inflammatory mediators, eosinophil activity, and mast cell degranulation. This reduces airway inflammation, edema, and hyper‑responsiveness, leading to better airflow and fewer symptoms.

The dose of Miflonide Breezhaler is individualized by the prescribing healthcare professional based on the severity of the disease, patient age, and response to therapy. Patients should follow the exact regimen written on their prescription and consult their clinician for any adjustments.

Budesonide is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies the potential risk. Limited data suggest minimal transfer into breast milk, but a clinician should evaluate the risk‑benefit ratio for nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Miflonide Breezhaler delivers budesonide via a dry‑powder Breezhaler device, offering consistent dose delivery and rapid onset. Compared with other inhaled corticosteroids such as fluticasone or beclomethasone, budesonide has a slightly lower systemic bioavailability, which may reduce the risk of systemic side effects while providing comparable efficacy in controlling asthma and COPD.

Store Miflonide Breezhaler at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and excessive heat. Keep the device away from direct sunlight and do not expose it to freezing conditions. Ensure the inhaler is kept out of reach of children.

The patient inhales the powdered medication through the Breezhaler device by placing the mouthpiece in the mouth, sealing lips around it, and inhaling sharply and deeply. After each dose, the device should be closed and stored as instructed. Patients are advised to rinse their mouth with water and spit out the rinse to reduce oral side effects.

Serious risks, though rare, include paradoxical bronchospasm (a sudden worsening of breathing), adrenal suppression leading to reduced cortisol production, and severe allergic reactions such as anaphylaxis or angioedema. Patients should seek immediate medical attention if they experience sudden breathlessness, severe swelling, or signs of an allergic reaction.

Miflonide Breezhaler should not be used by individuals with a known hypersensitivity to budesonide, other inhaled corticosteroids, or any component of the formulation. It is also contraindicated in patients who have experienced a severe paradoxical bronchospasm after using an inhaled corticosteroid. Clinicians should evaluate each patient’s medical history before prescribing.